ClearPoint Neuro Reports Second Quarter 2026 Results
ClearPoint Neuro reported Q2 2026 revenue of $10.9 million, an 18% increase year-over-year, driven by the IRRAflow acquisition and increased disposables sales, though the net loss widened to $11.3 million. The company adjusted its full-year 2026 revenue guidance to $48.0 million to $52.0 million to prioritize investment in clinical capacity and preclinical services at the new ClearPoint Advanced Laboratories facility rather than traditional sales expansion.
Key figures
- Revenue
- 10880000
- Guidance
- 2026 revenue $48.0M - $52.0M
- Revenue Yoy
- 18%
- Gross margin
- 62%
- Operating cash burn
- 15000000
- Cash and equivalents
- 29400000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.